Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Type I Diabetes I: Introduction

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...

Type I Diabetes II: Pathophysiology

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Type II Diabetes I: Introduction

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...

Type I Diabetes III: Clinical Manifestations

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Reduced display of conformational epitopes in the N-terminal truncated GAD65 isoform: relevance for people with stiff person syndrome or DQ8/8-positive Type 1 diabetes mellitus.

Diabetic medicine : a journal of the British Diabetic Association·2018

Same author

The Better Diabetes Diagnosis (BDD) study - A review of a nationwide prospective cohort study in Sweden.

Diabetes research and clinical practice·2018

Same author

Different DRB103:01-DQB102:01 haplotypes confer different risk for celiac disease.

HLA·2017

Same author

Altered regulatory T cell phenotype in latent autoimmune diabetes of the adults (LADA).

Clinical and experimental immunology·2016

Same author

Pancreas volume and fat fraction in children with Type 1 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2016

Same author

Non-HLA type 1 diabetes genes modulate disease risk together with HLA-DQ and islet autoantibodies.

Genes and immunity·2015

Search research articles

Related Experiment Video

Updated: Jun 2, 2026

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

Vaccination against type 1 diabetes.

H E Larsson¹, Å Lernmark

¹Department of Clinical Sciences, Lund University/CRC, Skåne University Hospital SUS, Malmö, Sweden.

Journal of Internal Medicine

|April 13, 2011

Summary

Type 1 diabetes onset follows islet autoimmunity, signaled by autoantibodies. Autoantigen-specific immunotherapy, like GAD65, shows promise in preserving beta-cell function post-diagnosis.

Area of Science:

Immunology
Endocrinology
Diabetology

Background:

Type 1 diabetes (T1D) onset is preceded by islet autoimmunity, characterized by autoantibodies against pancreatic islet beta cells.
The presence of multiple autoantibodies increases the risk of progressing to clinical T1D.
Insulitis at clinical onset may limit the effectiveness of immunosuppressive therapies.

Purpose of the Study:

To evaluate the potential of autoantigen-specific immunotherapy in managing T1D.
To explore mechanisms underlying immunotherapy efficacy, such as T regulatory cell induction.
To assess the safety and future applications of immunotherapy in T1D prevention and treatment.

Main Methods:

Administration of alum-formulated GAD65 (Diamyd®) as autoantigen-specific immunotherapy.

More Related Videos

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

Related Experiment Videos

Last Updated: Jun 2, 2026

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

Monitoring of beta-cell function and immune responses in clinical trials.

Analysis of safety data from past and ongoing clinical trials.

Main Results:

Autoantigen-specific immunotherapy with GAD65 demonstrates potential in reducing beta-cell function loss after T1D clinical onset.
Clinical trials involving this immunotherapy have shown a favorable safety profile.
Potential mechanisms involve the induction of regulatory T cells that may dampen autoimmune responses.

Conclusions:

Autoantigen-specific immunotherapy, particularly with GAD65, offers a promising therapeutic strategy for T1D.
Future trials may explore combination immunotherapies to enhance efficacy in preventing T1D onset or preserving beta-cell function in newly diagnosed patients.